CN115105423B - 具有抗炎抗敏活性的组合物及其应用 - Google Patents
具有抗炎抗敏活性的组合物及其应用 Download PDFInfo
- Publication number
- CN115105423B CN115105423B CN202210842014.2A CN202210842014A CN115105423B CN 115105423 B CN115105423 B CN 115105423B CN 202210842014 A CN202210842014 A CN 202210842014A CN 115105423 B CN115105423 B CN 115105423B
- Authority
- CN
- China
- Prior art keywords
- composition
- skin
- serine
- inflammatory
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 18
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 35
- -1 inositol glycerophosphate choline salt Chemical class 0.000 claims abstract description 30
- 239000004381 Choline salt Substances 0.000 claims abstract description 21
- 235000019417 choline salt Nutrition 0.000 claims abstract description 21
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims abstract description 19
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960000367 inositol Drugs 0.000 claims abstract description 15
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims description 31
- 206010015150 Erythema Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 13
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 231100000321 erythema Toxicity 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000000686 essence Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 35
- 210000003491 skin Anatomy 0.000 description 42
- 230000000052 comparative effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 16
- 229920002674 hyaluronan Polymers 0.000 description 16
- 229960003160 hyaluronic acid Drugs 0.000 description 16
- PTZZCYHESHNXFL-SECXAADESA-M [(2R)-2,3-dihydroxypropyl] [(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl] phosphate 2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.OC[C@@H](O)COP([O-])(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O PTZZCYHESHNXFL-SECXAADESA-M 0.000 description 12
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010050808 Procollagen Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 229940100460 peg-100 stearate Drugs 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DWMGLUVISSMERV-BBIVZNJYSA-N (2r)-2-[(1s)-2-[dihydroxy(methyl)silyl]oxy-1-hydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound C[Si](O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWMGLUVISSMERV-BBIVZNJYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RECMXJOGNNTEBG-UHFFFAOYSA-N 1-phenylmethoxyethanol Chemical compound CC(O)OCC1=CC=CC=C1 RECMXJOGNNTEBG-UHFFFAOYSA-N 0.000 description 1
- HUYSCRCIPIWDPL-UHFFFAOYSA-N 2,3-dipentylbenzene-1,4-diol Chemical compound CCCCCC1=C(O)C=CC(O)=C1CCCCC HUYSCRCIPIWDPL-UHFFFAOYSA-N 0.000 description 1
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 description 1
- KQNFZEVUCSXNTH-UHFFFAOYSA-N 2-(2-amino-2-oxoethyl)sulfanylacetamide Chemical compound NC(=O)CSCC(N)=O KQNFZEVUCSXNTH-UHFFFAOYSA-N 0.000 description 1
- IUNVCWLKOOCPIT-UHFFFAOYSA-N 6-methylheptylsulfanyl 2-hydroxyacetate Chemical compound CC(C)CCCCCSOC(=O)CO IUNVCWLKOOCPIT-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- KQZNFGJQTPAURD-NBWQQBAWSA-N ascorbyl dipalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(O)=C1O KQZNFGJQTPAURD-NBWQQBAWSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- AMQDHYXCJCIBQJ-YCWPWOODSA-L disodium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-oxido-5-oxo-2h-furan-4-yl] sulfate Chemical compound [Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OS([O-])(=O)=O)=C1[O-] AMQDHYXCJCIBQJ-YCWPWOODSA-L 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000341 effect on erythema Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- HBPVKGYQTMAQDM-UHFFFAOYSA-N ethene;2-hydroxybenzoic acid Chemical compound C=C.OC(=O)C1=CC=CC=C1O HBPVKGYQTMAQDM-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ATJVZXXHKSYELS-FNORWQNLSA-N ethyl (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-FNORWQNLSA-N 0.000 description 1
- 229940027504 ethyl ferulate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- ATJVZXXHKSYELS-UHFFFAOYSA-N ferulic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- IXDBUVCZCLQKJF-UHFFFAOYSA-N hexadecyl 3-(3-hexadecoxy-3-oxopropyl)sulfanylpropanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCC IXDBUVCZCLQKJF-UHFFFAOYSA-N 0.000 description 1
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940095136 methylsilanol ascorbate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940116905 potassium ascorbyl tocopheryl phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- MZHULIWXRDLGRR-UHFFFAOYSA-N tridecyl 3-(3-oxo-3-tridecoxypropyl)sulfanylpropanoate Chemical compound CCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCC MZHULIWXRDLGRR-UHFFFAOYSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- WGKLOLBTFWFKOD-UHFFFAOYSA-N tris(2-nonylphenyl) phosphite Chemical compound CCCCCCCCCC1=CC=CC=C1OP(OC=1C(=CC=CC=1)CCCCCCCCC)OC1=CC=CC=C1CCCCCCCCC WGKLOLBTFWFKOD-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请公开了一种具有抗炎抗敏活性的组合物及其应用。本申请中，所述组合物包括：丝氨酸(PuriCerine)和甘油磷酸肌醇胆碱盐(PuriGPI)，本申请提供的组合物，具有显著的抗炎抗敏感活性，和更低的副作用。
Description
技术领域
本发明涉及生物化学领域，特别涉及具有抗炎抗敏活性的组合物及其应用。
背景技术
皮肤敏感是多种因素诱发的主观感觉症状的皮肤状态，对刺激的耐受性降低。当受到外界刺激时，会释放炎性介质，引起红斑、肿胀以及刺痛等现象。当前化妆品市场名目繁多，刺激类产品不在少数，同时社会习惯以及生活环境可能会因其皮肤刺激，导致发炎和过敏等问题。现有技术中，治疗皮肤炎症和过敏的产品存在吸收差、抗炎抗敏效果不佳、含有激素副作用明显等问题，例如倍他米松和地塞米松活性虽然抗炎效果好，但是激素引起的副作用明显，容易产生耐药性。此外部分产品中含有的草药提取物成分还可能造成炎症和敏感的进一步加重，阻碍皮肤自身免疫调节。因此，本领域尚需开发一种有效组织皮肤过敏及炎症，迅速消红、止痒、止痛的产品。
发明内容
本发明的目的在于提供一种具有抗炎抗敏活性的组合物及其应用。
为解决上述技术问题，本发明的第一方面，提供了一种具有抗炎抗敏活性的组合物，所述组合物包括：
丝氨酸(PuriCerine)和
甘油磷酸肌醇胆碱盐(PuriGPI)。
在一些优选的方案中，所述丝氨酸和所述甘油磷酸肌醇胆碱盐的质量百分比为2：(2.5-3.5)。
本发明的第二方面，提供了一种化妆品，所述化妆品包括本发明第一方面所述组合物，和化妆品中可接受的辅料。
在一些优选的方案中，相对于所述化妆品的总质量，所述组合物的质量比为0.1至99％。
在一些优选的方案中，所述化妆品可接受的辅料包括抗氧化剂、防腐剂、保湿剂和表面活性剂。
在一些优选的方案中，所述化妆品选自以下任一种形式：化妆水、乳液、化妆霜、精华、面膜、膏状凝胶、喷雾、香皂、洗面奶、沐浴露、洗发露、护发素、粉底、粉霜、身体乳或按摩膏。
本发明的第三方面，提供了一种药物组合物，所述药物组合物包括本发明第一方面所述组合物，和药学上可接受的载体。
本发明的第四方面，提供了本发明第一方面所述组合物或本发明第三方面所述药物组合物的用途，包括：
(i)治疗银屑病；
(ii)治疗红疹；
(iii)制备治疗银屑病的药物；
(iv)制备治疗红疹的药物；
(v)提升前胶原表达水平；和/或
(vi)抑制MMP表达水平。
本发明的第五方面，提供了一种使皮肤抗炎和/或抗敏的方法，所述方法包括步骤：
向受试者施用本发明第一方面所述组合物；或
向受试者施用本发明第二方面所述化妆品；或
向受试者施用本发明第三方面所述药物组合物。
在一些优选的方案中，所述方法为非治疗目的的。
在一些优选的方案中，所述皮肤为人的皮肤、实验动物的皮肤或实验室培养的皮肤组织。
本发明的第六方面，提供了一种提高皮肤透明质酸吸收水平的方法，所述方法包括步骤：
将透明质酸和本发明第一方面所述组合物联合施用于皮肤。
在一些优选的方案中，所述方法为非治疗目的的。
在一些优选的方案中，所述皮肤为人的皮肤、实验动物的皮肤或实验室培养的皮肤组织。
本发明相对于现有技术而言，至少具有下述优点：
(1)本发明提供的组合物，具有显著的抗炎抗敏感活性，和更低的副作用；
(2)本发明提供的组合物，可应用于消炎抗敏、去红血丝、消除红疹、治疗银屑病、抗老去皱、保湿补水、抗蓝光、抗颗粒物污染；
(3)本发明提供的组合物，制备获得的产品吸收好、稳定性高、生物利用度高；
(4)本发明提供的组合物，与透明质酸联用可促进其吸收。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
一个或多个实施例通过与之对应的附图中的图片进行示例性说明，这些示例性说明并不构成对实施例的限定。
图1是根据本发明实施例中施用不同产品皮肤局部祛红血丝效果示意图；
图2是根据本发明实施例中施用不同产品皮肤红疹消除效果示意图；
图3是根据本发明实施例中银屑病患者施用不同产品发红率统计图；
图4是根据本发明实施例中银屑病患者施用不同产品发痒率统计图；
图5是根据本发明实施例中组合物对紫外线诱导前胶原和MMP的表达量影响示意图；
图6是根据本发明实施例中组合物对紫外线诱导前胶原和MMP的转录水平影响示意图；
图7是根据本发明实施例中施用不同产品对皮肤透明质酸含量影响示意图；
图8是根据本发明实施例中施用不同产品对皮肤角质层含水量影响示意图；
图9是根据本发明实施例中蓝光照射下施用不同产品对细胞内ROS的水平的影响示意图；
图10是根据本发明实施例中颗粒物环境下施用不同产品对细胞内ROS的水平的影响示意图；
图11是根据本发明实施例中组合物对透明质酸渗透率的影响示意图；
图12是根据本发明实施例中皮肤明场组织呈像图。
具体实施方式
皮肤敏感是多种因素诱发的主观感觉症状的皮肤状态，对刺激的耐受性降低。当受到外界刺激时，会释放炎性介质，引起红斑、肿胀以及刺痛等现象。皮肤反复性炎症和敏感一直十分棘手难治的皮肤问题。现有技术中效果较好的倍他米松和地塞米松活性中含有激素，容易产生副作用，而其他的产品抗炎抗敏感效果并不明显或者起效时间十分长，过程中伴随着皮肤蜕皮、脱水等诸多问题。本发明人经过广泛而深入的研究，开发了一种安全有效的具有抗炎抗敏活性的组合物，所述组合物包括：丝氨酸(PuriCerine)和甘油磷酸肌醇胆碱盐(PuriGPI)。本发明的组合物，以天然生物活性物质为原料，副作用低，且两种组分混合产生出乎意料的协同作用，大幅提升抗炎和抗敏活性。
组合物
本发明中具有抗炎抗敏活性的组合物包括丝氨酸(DL-Serine,CAS号：302-84-1；可使用商品名如PuriCerine的市售产品)和甘油磷酸肌醇胆碱盐(Glycerophosphoinositol choline,CAS号：425642-32-6；可使用商品名如PuriGPI的市售产品)。二者可以以任一种比例相互混合，前述混合可以是互溶或不互溶的形式。但优选地，所述组合物中，所述甘油磷酸肌醇胆碱盐的量大于所述丝氨酸的量；更优选地，所述丝氨酸和所述甘油磷酸肌醇胆碱盐的质量百分比为2：(2.5-3.5)，例如2:3。
丝氨酸和甘油磷酸肌醇胆碱盐作为活性成分可以溶解于任一种可溶介质(溶剂)中构成本发明的组合物。在本发明的一些实施方式中，所述组合物包括丝氨酸、甘油磷酸肌醇胆碱盐和水。丝氨酸和甘油磷酸肌醇胆碱盐在组合物中的含量不做特别限制，但优选地，所述组合物中，所述丝氨酸的质量百分含量优选为1至50％；和/或，所述组合物中，所述甘油磷酸肌醇胆碱盐的质量百分含量为1至50％。
化妆品和使用方法
本发明中，化妆品包括上述的组合物，和化妆品中可接受的辅料。
在一些优选的方案中，所述化妆品中可接受的辅料选自溶剂、增溶剂、防腐剂、抗氧化剂、pH调节剂、促渗剂、脂质体、保湿剂、增稠剂、螯合剂、肤感调节剂、表面活性剂、乳化剂、推进/抛射剂、香精、色素，以及其他功效添加剂。例如本发明的一个实施例中，所述化妆品中可接受的辅料为抗氧化剂、防腐剂、保湿剂、表面活性剂和抗炎剂。
在一些优选的方案中，所述化妆品选自以下任一种形式：化妆水、乳液、化妆霜、精华、面膜、膏状凝胶、喷雾、香皂、洗面奶、沐浴露、洗发露、护发素、粉底、粉霜、身体乳或按摩膏。
在一些优选的方案中，相对于所述化妆品的总质量，所述组合物的质量百分含量为0.1至99％；优选为1至90％；更优选为1至90％；更优选为1至80％；更优选为1至70％；更优选为1至60％；更优选为1至50％；更优选为1至30％；更优选为1至15％；更优选为1至10％；更优选为1至9％；更优选为1至7％；更优选为1至6％；更优选为1至5％，例如：2％、3％、4％或5％。本发明中特别优选地，所述组合物的质量百分含量为1至5％。
作为防腐剂，非限制地可以选自对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯、苯甲酸酯、山梨酸、三氯生、三氯卡班等)、金属螯合剂。剂(如EDTA、NTA等)、蛋白水解酶、防腐剂(zincpyrythion、octropix等)、渗透促进剂(苯甲醇、苄氧基乙醇等)、增稠剂(羧乙烯基聚合物等)可含有羧甲基纤维素、聚乙烯醇、角叉菜胶、水溶性聚合物如明胶)、电解质、pH调节剂(缓冲剂如乳酸-乳酸钠和柠檬酸-柠檬酸钠)。
防腐剂在本发明的化妆品中的添加量优选为0.01～50重量％(以下简称为％)，特别优选为0.5～20％。
作为抗氧化剂，非限制地可以选自乙酰半胱氨酸、抗坏血酸、抗坏血酸多肽、二棕榈酸抗坏血酸酯、甲基硅烷醇果胶酯酸抗坏血酸酯、棕榈酸抗坏血酸酯、硬脂酸抗坏血酸酯、BHA、BHT、叔丁基氢醌、半胱氨酸、盐酸半胱氨酸、二戊基氢醌、二叔丁基氢醌、硫代二丙酸二鲸蜡酯、二油基生育酚甲基硅烷醇、硫酸抗坏血酸二钠、硫代二丙酸二硬脂酰酯、硫代二丙酸二(十三)酯、棓酸十二烷基酯、异抗坏血酸、抗坏血酸酯类、阿魏酸乙酯、阿魏酸、棓酸酯类、氢醌、巯基醋酸异辛酯、曲酸、抗坏血酸镁、抗坏血酸磷酸镁、抗坏血酸甲基硅烷醇酯；天然植物性药材抗氧化剂，诸如绿茶或葡萄子提取物、去甲二氢愈创木酸、棓酸辛酯、苯基硫代巯基乙酸、抗坏血酸生育酚磷酸钾、亚硫酸钾、棓酸丙酯、醌类、迷迭香酸、抗坏血酸钠、硫酸氢钠、异抗坏血酸钠、焦亚硫酸钠、亚硫酸钠、超氧化物歧化酶、硫代巯基乙酸钠、山梨醇糠醛、硫二甘醇、硫二甘醇酰胺、亚硫基二乙酸、亚硫基乙酸、硫羟乳酸、硫代水杨酸、tocophereth-5、tocophereth-10、tocophereth-12、tocophereth-18、tocophereth-50、生育酚、tocophersolan、乙酸生育酚酯、亚油酸生育酚酯、烟酸生育酚酯、琥珀酸生育酚酯和三(壬基苯基)亚磷酸盐中的至少一种。
抗氧化剂在本发明的化妆品中的添加量优选为0.01～50重量％(以下简称为％)，特别优选为0.5～20％。
作为保湿剂，非限制地可以选自甘油、神经酰胺或其类似结构物质、胆固醇酯、山梨糖醇、木糖醇、甘油、martitol、丙二醇、1,3-丁二醇等其实例包括1,4-丁二醇、吡咯烷酮羧酸钠、乳酸、乳酸钠、聚氧丙烯脂肪酸酯、聚乙二醇中的至少一种。本发明中特别优选地，保湿剂为甘油和丙二醇。
保湿剂在本发明的化妆品中的添加量优选为0.01～50重量％(以下简称为％)，特别优选为0.5～20％。
作为抗炎剂，非限制地可以选自水杨酸甲酯、水杨酸乙二醇酯、消炎痛、布洛芬、尿囊素、氯化溶菌酶、愈创木灵、γ-香豆素、醋酸生育酚、甘草酸、甘草酸二钾、甘草次酸及其盐。这些可以单独使用或两种以上组合使用。本发明中特别优选地，所述抗炎剂为甘草酸二钾。
抗炎剂在本发明的化妆品中的添加量优选为0.001～5％，特别优选为0.1～2％。
作为表面活性剂，非限制地可以是辛酸/癸酸甘油三酯、棕榈酸异辛酯、聚二甲基硅氧烷、鲸蜡硬脂基葡糖苷/鲸蜡硬脂醇、甘油硬脂酸酯/PEG-100硬脂酸酯、聚丙烯酸13/聚异丁烯/聚山梨酸酯-20等，本发明中特别优选地，所述表面活性剂为辛酸/癸酸甘油三酯、棕榈酸异辛酯、聚二甲基硅氧烷、鲸蜡硬脂基葡糖苷/鲸蜡硬脂醇、甘油硬脂酸酯/PEG-100硬脂酸酯、聚丙烯酸13/聚异丁烯/聚山梨酸酯-20的组合。
表面活性剂在本发明的化妆品中的添加量优选为1～50％，特别优选为10～30％。
本发明中所用的术语“化妆品”是指以涂抹、喷洒或者其他类似方法，散布于人体表面的任何部位，如皮肤、毛发、指趾甲、唇齿等，以达到清洁、保养、美容、修饰和改变外观，或者修正人体气味，保持良好状态为目的的化学工业品或精细化工产品。根据本发明的优选实施方式中，所述化妆品包括：保湿化妆品、具有保湿功效的抗炎症化妆品，以及具有保湿功效的抗衰老或美白化妆品。
应将化妆品定期地局部施用在任何需要使用获得所需结果必不可少的频率和用量治疗的皮肤面积上。优选将所述的化妆品每天至少施用一次、最优选每天施用两次。治疗的频率取决于皮肤损害或恶化的程度、使用者皮肤的反应性、活性组分在化妆品中的浓度、用于将活性组分转运入角质层的载体的有效性、通过与衣服的物理性接触而除去该制品或通过出汗或其它内部或外部液体而除去该制品的便利性以及对使用者类型的便利性。以所述化妆品的总重为基准，诸如本文所述的化妆品这样相对简单的生化活性物质的典型浓度可以在约0.01％-约5.0％(重量)的范围，且应将该制品以等于约1.0mg/cm2皮肤-约20.0mg/cm2皮肤的比例施用于皮肤。以所述化妆品组合物的总重为基准，优选该配方应含有约0.39％-约0.78％。最优选该配方应含有约0.78％的活性组分且以约5.0mg/cm2皮肤的比例将其施用于皮肤。
本发明中化妆品的作用，包括但不限于：消炎抗敏、去红血丝、抗老去皱、保湿补水、抗蓝光、抗颗粒物污染。
药物组合物
本发明中，药物组合物包括上述的组合物，和药学上可接受的载体。
作为药学上可接受的载体，非限制地可选自乳糖、葡萄糖、蔗糖、山梨糖醇、甘露醇、淀粉、rubber arable、磷酸钾、arginate、明胶、硅酸钾、微晶体纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆、甲基纤维素、甲基羟基苯甲酸酯、丙基羟基苯甲酸酯、滑石、硬脂酸镁和矿物油。根据本发明的药物组合物可以进一步包括润滑剂、润湿剂、甜味剂、调味剂、乳化剂、悬浮剂和防腐剂中至少一种。合适的药物学上可接受的载体和制剂的详细内容可以在Remington’s Pharmaceutical Sciences(第19版，1995)中找到。
本发明的药物组合物可以与如上所述的药物学上可接受的载体和/或介质一起配制，最终提供单位剂型和多剂量形式的几种形式。制剂的非限制性实例包括但不限于口服制剂，如粉末、颗粒、片剂、胶囊、悬浮液、乳液、糖浆和气雾剂，外用制剂，如膏剂和霜剂、栓剂和无菌注射液，优选为外用膏基、霜基、凝胶、液态涂覆剂。
适应症
本发明中，组合物和药物组合物的用途包括：
(i)治疗银屑病；
(ii)治疗红疹；
(iii)制备治疗银屑病相关药物；
(iv)制备治疗红疹相关药物；
(v)提升前胶原表达水平；和/或
(vi)抑制MMP表达水平。
治疗方法
本发明中的“组合物”或“药物组合物”的施用对象为哺乳动物，包括但不限于，灵长动物(例如，人)、牛、绵羊、山羊、马、狗、猫、兔、大鼠、小鼠等。在特定的实施方式中，该对象为人。
为适应施用对象的特点和治疗的需求，本发明中的“组合物”或“药物组合物”优选被制成药剂的形式施用；给药途径优选为非肠道给药，例如为外敷、涂抹、皮下注射；给药的方式优选局部施用。
本发明中对施用对象施用安全有效量的“组合物”或“药物组合物”，这里的安全有效量是指20至2000mg/kg，优选为50至1000mg/kg，更优选为100至800mg/kg；例如：100mg/kg、150mg/kg、200mg/kg、250mg/kg、300mg/kg、350mg/kg、400mg/kg、450mg/kg、500mg/kg、550mg/kg、600mg/kg、650mg/kg、700mg/kg、750mg/kg或800mg/kg，前述安全有效量均为活性成分的含量。在一些实施例中，所述的安全有效量为50-200mg/kg(小鼠)，或500-1000mg/kg(人)。
当治疗银屑病时，本发明中“组合物”或“药物组合物”施用频率为每日1至3次，例如早或晚1次、早晚各一次共2次或早中晚各一次共3次；持续施用不少于1天，优选为不少于10天，优选不少于20天，优选不少于30天，最优选不少于60天。
当治疗红疹时，本发明中“组合物”或“药物组合物”施用频率为每日1至3次，例如早或晚1次、早晚各一次共2次或早中晚各一次共3次；持续施用不少于1天，优选为不少于3天，优选不少于5天，优选不少于7天，最优选不少于7天。
为使本发明实施例的目的、技术方案和优点更加清楚，下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数是重量百分比和重量份数。以下实施例中所用的实验材料和试剂如无特别说明均可从市售渠道获得。
除非另有指明，本文所用的技术和科学术语具有与本申请所属技术领域的普通技术人员通常理解的相同含义，需要注意的是，本文所用的术语仅为了描述具体实施方式，而非意图限制本申请的示例性实施方式。
实施例1、组合物的制备
将丝氨酸2g、甘油磷酸肌醇胆碱盐3g和水75g混合，即得到组合物。
实施例2、含有组合物的护肤制剂的制备
以每100g由下述组分制成：GTCC辛酸/癸酸甘油三酯5g、棕榈酸异辛酯3g、聚二甲基硅氧烷(粘度100型号)1g、丝氨酸2g、甘油磷酸肌醇胆碱盐3g、Montanov 68(鲸蜡硬脂基葡糖苷/鲸蜡硬脂醇)2g、Simusol 165(甘油硬脂酸酯/PEG-100硬脂酸酯)1g、甘草酸二钾0.1g、丙二醇3g、甘油3g、SEPIPLUS 400(聚丙烯酸13/聚异丁烯/聚山梨酸酯-20)1g、防腐剂1g、水74.9g。
对比例1、丝氨酸的水溶液
使用丝氨酸5g和水75g混合。
对比例2、甘油磷酸肌醇胆碱盐的水溶液
使用甘油磷酸肌醇胆碱盐5g和水75g混合。
实施例3、祛红血丝效果测试
取志愿者面部一块红血丝较为严重的区域，等分为四个部分，分别记为1、2、3、4。每个区域分别不施加任何产品、对比例1制备的丝氨酸水溶液、对比例2制备的甘油磷酸肌醇胆碱盐水溶液和施加实施例1制备的组合物，作用7天后拍照记录，结果见图1。
图1中，A对应1，为不施加组合物7天后的对照组；B对应2，为施加对比例1作用7天后；C对应3，为施加对比例2作用7天后；D对应4，为施加实施例1作用7天后。
由图1可知，相比不施用任何产品，施加丝氨酸水溶液或者甘油磷酸肌醇胆碱盐水溶液均在一定程度上减轻了红血丝的严重程度；施加丝氨酸和甘油磷酸肌醇胆碱盐的组合物，祛红血丝效果十分显著，7天后几乎看不见红血丝。
实施例4、消除红疹效果测试
取志愿者面部一块红疹较为严重的区域，等分为四个部分，分别记为1、2、3、4。每个区域分别不施加任何产品、每日一次施加对比例1制备的丝氨酸水溶液、每日一次施加对比例2制备的甘油磷酸肌醇胆碱盐水溶液和每日一次施加施加实施例1制备的组合物，作用7天后拍照记录，结果见图2。
图2中，A对应1，为不施加组合物7天后的对照组；B对应2，为施加对比例1作用7天后；C对应3，为施加对比例2作用7天后；D对应4，为施加实施例1作用7天后。
由图2可知，相比不施用任何产品，施加丝氨酸水溶液或者甘油磷酸肌醇胆碱盐水溶液对红疹几乎没有效果，而施加丝氨酸和甘油磷酸肌醇胆碱盐的组合物，7天后红疹症状显著减轻。
实施例5、银屑病治疗效果测试
银屑病是一种慢性炎症皮肤病，临床表现以红斑、瘙痒、鳞屑为主。本实施例以皮肤发红、发痒作为银屑病严重程度的指标，选取20名患有银屑病患者作为志愿者分成四组，其皮肤发红发痒的严重程度接近，前三组病患分别每日在患病区域涂抹一次实施例1的组合物、对比例1的丝氨酸水溶液或者对比例2的甘油磷酸肌醇胆碱盐水溶液，对照组不进行涂抹，持续60天，在第0、7、15、30、60天记录他们的发红率、发痒率。取平均值的方式计算数据并以折线图形式呈现，结果见图3和图4。
由图3和图4可知，相比不施加任何产品，施加丝氨酸水溶液或者甘油磷酸肌醇胆碱盐水溶液一定程度上减轻银屑病患者皮肤发红和瘙痒症状；施用丝氨酸和甘油磷酸肌醇胆碱盐的组合物，可以显著提升银屑病的治疗效果，使皮肤发红率和发痒率同时大幅降低，施用60天后发痒率指标接近于0％。
实施例6、抗衰老测试
衰老过程中，特征性的表现为前胶原表达降低和基质金属蛋白酶(MMP)的增加。MMP是由表皮角质形成细胞和真皮成纤维细胞分泌的一组基质降解酶。胶原蛋白的变化被认为是皱纹形成的原因。
本实施例中验证了实施例1组合物相比安慰剂可以显著降低抑制基质金属蛋白酶(MMP)的增加，并且可以促进前胶原的表达。
取60岁志愿者的角质细胞进行培养，将培养的角质细胞分别放两个培养皿，分别施加VE和施加实施例1制备的组合物，后紫外线持续照射4小时后，测定前胶原和MMP的表达量。结果见图5。图5中PS组施用实施例1的组合物；VE组施用维生素E。
由图5可知，相比VE对照组，施加实施例1组合物显着刺激前胶原启动子活性并抑制紫外线诱导的MMP-1启动子活化。
通过进一步测定细胞中前胶原和MMP的mRNA表达，见过见图6。结果表明实施例1制备的组合物预处理可提升紫外线诱导的前胶原转录水平和抑制MMP-1表达。
实施例7、保湿补水效果测试
本实施例中，皮肤的持水能力以皮肤透明质酸含量和角质层含水量为评判指标。选取志愿者面部一块区域，等分为四个部分，四个部分分别不施加任何产品、施加对比例1制备的丝氨酸水溶液、对比例2制备的甘油磷酸肌醇胆碱盐水溶液和施加实施例1制备的组合物。在第15、30、60、120分钟时测定含水量，并在120分钟后测定皮肤透明质酸含量，结果见图7和图8。
由图7和图8可知，相比不施用任何产品或仅施用单一的丝氨酸水溶液或甘油磷酸肌醇胆碱盐水溶液，施用了实施例1的组合物可显著增加皮肤透明质酸含量和角质层含水量。
实施例8、抗蓝光效果测试
蓝光会激活色素细胞，增加活性氧的产生。此外，线粒体受到蓝光的破坏，造成氧化应激和功能障碍，导致皮肤衰老。本实施例在蓝光照射下进行，将培养的角质细胞分别放入四个培养皿，分别不施加任何产品、施加对比例1制备的丝氨酸水溶液、对比例2制备的甘油磷酸肌醇胆碱盐水溶液和施加实施例1制备的组合物，持续照射4小时后，测定该区域内细胞ROS水平，结果见图9。
由图9可知，相比不施用任何产品或仅施用单一的丝氨酸水溶液或甘油磷酸肌醇胆碱盐水溶液，施用了实施例1的组合物降低细胞内ROS的水平，说明实施例1的组合物抗蓝光效果显著。
实施例9、抗颗粒物污染效果测试
颗粒物(PM2.5)等空气污染物会诱导皮肤细胞产生活性氧，是导致皮肤问题的外部环境因素之一。流行病学研究表明，色素斑点和皱纹在空气污染物水平较高地区的人中很常见。本实施例在充满颗粒物环境下进行，将培养的角质细胞分别放入四个培养皿，分别不施加任何产品、施加对比例1制备的丝氨酸水溶液、对比例2制备的甘油磷酸肌醇胆碱盐水溶液和施加实施例1制备的组合物，持续放置4小时后，测定该区域内细胞ROS水平，结果见图10。
由图10可知，相比不施用任何产品或仅施用单一的丝氨酸水溶液或甘油磷酸肌醇胆碱盐水溶液，施用了实施例1的组合物降低细胞内ROS的水平，说明在颗粒物环境中，实施例1的组合物能够抑制皮肤细胞内的ROS的产生，延缓皮肤衰老。
实施例10、透明质酸渗透效果测试
本实施例中验证了实施例1组合物与透明质酸共用可协同促进提升透明质酸在人体皮肤的渗透率。选取志愿者面部一块区域，等分为两个部分，第一区域仅施加透明质酸，第二区域施加等量的透明质酸并且施加实施例1的组合物，并在120分钟后测定皮肤透明质酸含量，结果见图11。120分钟后两个区域的皮肤明场组织呈像图见图12，左边为第一区域，右边为第二区域。
由图11和12可知，实施例1的组合物显著促进皮肤透明质酸的吸收，可与透明质酸协同使用提升皮肤的含水量。
本领域的普通技术人员可以理解，上述各实施方式是实现本发明的具体实施例，而在实际应用中，可以在形式上和细节上对其作各种改变，而不偏离本发明的精神和范围。
Claims (7)
1.一种具有抗炎抗敏活性的组合物，其特征在于，所述组合物由：
丝氨酸和甘油磷酸肌醇胆碱盐组成；
其中，所述丝氨酸和所述甘油磷酸肌醇胆碱盐的质量百分比为2：（2.5-3.5）。
2.一种化妆品，其特征在于，所述化妆品包括权利要求1所述的组合物，和化妆品中可接受的辅料。
3.根据权利要求2所述的化妆品，其特征在于，相对于所述化妆品的总质量，所述组合物的质量百分含量为0.1至99%。
4.根据权利要求2所述的化妆品，其特征在于，所述化妆品可接受的辅料包括抗氧化剂、防腐剂、保湿剂和表面活性剂。
5.根据权利要求2所述的化妆品，其特征在于，所述化妆品选自以下任一种形式：化妆水、乳液、化妆霜、精华、面膜、膏状凝胶、喷雾、香皂、洗面奶、沐浴露、洗发露、护发素、粉底、粉霜、身体乳或按摩膏。
6.一种药物组合物，其特征在于，所述药物组合物包括权利要求1所述的组合物，和药学上可接受的载体。
7.权利要求1所述的组合物的用途，其特征在于，用于：
（i）制备治疗银屑病的外用制剂；
（ii）制备治疗红疹的外用制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210842014.2A CN115105423B (zh) | 2022-07-18 | 2022-07-18 | 具有抗炎抗敏活性的组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210842014.2A CN115105423B (zh) | 2022-07-18 | 2022-07-18 | 具有抗炎抗敏活性的组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115105423A CN115105423A (zh) | 2022-09-27 |
| CN115105423B true CN115105423B (zh) | 2023-12-22 |
Family
ID=83332640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210842014.2A Active CN115105423B (zh) | 2022-07-18 | 2022-07-18 | 具有抗炎抗敏活性的组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115105423B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
| CN105687061A (zh) * | 2016-04-15 | 2016-06-22 | 广州宝生堂化妆品有限公司 | 一种具有修复肌肤功能的组合物 |
| CN108938498A (zh) * | 2018-09-25 | 2018-12-07 | 广州好润生物科技有限公司 | 一种具有抑制组胺释放的抗敏修复组合物及其制备方法和应用 |
| CN111700853A (zh) * | 2020-07-22 | 2020-09-25 | 广州澳希亚实业有限公司 | 一种具有抗敏修复功效的化妆品组合物及其应用 |
| CN112120986A (zh) * | 2020-10-27 | 2020-12-25 | 广东芭薇生物科技股份有限公司 | 一种眼部修护组合物及含有该组合物的眼霜 |
| CN112972354A (zh) * | 2021-02-26 | 2021-06-18 | 广东梵蜜琳生物科技有限公司 | 一种护肤组合物及其在化妆品中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008005533A2 (en) * | 2006-07-06 | 2008-01-10 | Aaron Thomas Tabor | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
| WO2021016330A2 (en) * | 2019-07-22 | 2021-01-28 | Oneskin, Inc. | Polypeptides having anti-senescent effects and uses thereof |
-
2022
- 2022-07-18 CN CN202210842014.2A patent/CN115105423B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (zh) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-丝氨酸作为药物用于预防和/或治疗皮肤炎症应答的用途 |
| CN105687061A (zh) * | 2016-04-15 | 2016-06-22 | 广州宝生堂化妆品有限公司 | 一种具有修复肌肤功能的组合物 |
| CN108938498A (zh) * | 2018-09-25 | 2018-12-07 | 广州好润生物科技有限公司 | 一种具有抑制组胺释放的抗敏修复组合物及其制备方法和应用 |
| CN111700853A (zh) * | 2020-07-22 | 2020-09-25 | 广州澳希亚实业有限公司 | 一种具有抗敏修复功效的化妆品组合物及其应用 |
| CN112120986A (zh) * | 2020-10-27 | 2020-12-25 | 广东芭薇生物科技股份有限公司 | 一种眼部修护组合物及含有该组合物的眼霜 |
| CN112972354A (zh) * | 2021-02-26 | 2021-06-18 | 广东梵蜜琳生物科技有限公司 | 一种护肤组合物及其在化妆品中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115105423A (zh) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4522580B2 (ja) | 皮膚健全化剤 | |
| KR100603237B1 (ko) | 피부질환 예방 및 치료제 | |
| EP2244690B1 (en) | Topical compositions for treating inflammatory disorders, diseases and conditions | |
| US9980887B2 (en) | Compositions for use in treatment of hyperpigmentation and methods of use thereof | |
| EA009006B1 (ru) | Способ обработки кожи и композиция для косметической обработки кожи | |
| KR20100017333A (ko) | 화장료 유효 성분의 전달에 유용한 젤 | |
| JPH08333260A (ja) | 皮膚外用剤 | |
| US20090197819A1 (en) | Compositions for improving and repairing skin | |
| AU2009315771A1 (en) | Compound useful for treating cellulite | |
| WO2020006496A1 (en) | Bioactive compositions and methods for treating skin | |
| JPH09255547A (ja) | 皮膚外用剤 | |
| KR20090103992A (ko) | 감마-아미노 부티르산의 탈색제로서 용도 | |
| JP3881411B2 (ja) | 外用に適する組成物 | |
| CN115105423B (zh) | 具有抗炎抗敏活性的组合物及其应用 | |
| EP1635779B1 (en) | Cosmetic peeling method using urea | |
| JP2016179958A (ja) | 皮膚色素沈着抑制剤 | |
| JP2014210762A (ja) | 皮脂分泌抑制剤 | |
| US10449130B2 (en) | Method and composition for inhibiting aged skin | |
| US20050019354A1 (en) | Topical benfotiamine treatments | |
| JP2684561B2 (ja) | 色素沈着抑制剤 | |
| JPH09255546A (ja) | 皮膚外用剤 | |
| KR101661694B1 (ko) | 히드로퀴논을 포함하는 저자극성 피부 미백용 조성물 | |
| KR20070006626A (ko) | 피부의 국부조성물 | |
| KR20110060529A (ko) | 시클로헥산 디카르복실산 유도체를 함유하는 피부 외용제 조성물 | |
| WO2010137335A1 (ja) | α－リポ酸ナノ粒子を含有する、ターンオーバー促進用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |